Brief: Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity Of Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist

Medicenna Therapeutics

22/09/2022 13:04

Sept 22 (Reuters) - Medicenna Therapeutics Corp
 MDNA.TO :
    * MEDICENNA PRESENTS PRECLINICAL DATA DEMONSTRATING
ANTI-TUMOR
ACTIVITY OF ITS ANTI-PD1-IL-2 BISKIT AND LONG-ACTING IL-4/IL-13
SUPER-ANTAGONIST AT CYTOKINES 2022
    * MEDICENNA - QTRLY SINGLE AGENT ANTI-PD1-IL-2 BISKIT SHOWED
SUPERIOR EFFICACY COMPARED TO COMBINATION OF ANTI-PD1 ANTIBODY
WITH IL-2 SUPERKINE
    * MEDICENNA - QTRLY IL-4/IL-13 SUPER-ANTAGONIST DISPLAYED
MONOTHERAPY ACTIVITY IN MULTIPLE CANCER MODELS AND IN SYNERGY
WITH AN IL-2 SUPERKINE

Source text for Eikon:  ID:nGNX4fclQY 
Further company coverage:  MDNA.TO 
 ((Reuters.Briefs@thomsonreuters.com;))